Staging models in bipolar disorder: A systematic review of the literature

Clinical Psychopharmacology and Neuroscience

Volumn 14, Issue 2, 2016, Pages 117-130

  Muneer, Ather ^a  

^a RIPHAH INTERNATIONAL UNIVERSITY   (Pakistan)

Author keywords

Allostatic load; Biomarkers; Bipolar disorder; Neuroprogression; Staging

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; NEUROTROPHIC FACTOR;

BIPOLAR DISORDER; DATA ANALYSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE MARKER; GENETIC HETEROGENEITY; HUMAN; ILLNESS TRAJECTORY; IMAGE ANALYSIS; MEDICAL RESEARCH; NEUROIMAGING; NONBIOLOGICAL MODEL; NONHUMAN; OXIDATIVE STRESS; PROGENY; PROSPECTIVE STUDY; REVIEW; STAGING; STAGING MODEL; SYSTEMATIC REVIEW;

EID: 84969134712     PISSN: 17381088     EISSN: 20934327     Source Type: Journal    
DOI: 10.9758/cpn.2016.14.2.117     Document Type: Review

References (88)

1. Gonzalez R. The relationship between bipolar disorder and biological rhythms. J Clin Psychiatry 2014;75:e323-e331
2. Nivoli AM, Murru A, Pacchiarotti I, Valenti M, Rosa AR, Hidalgo D, et al. Bipolar disorder in the elderly: a cohort study comparing older and younger patients. Acta Psychiatr Scand 2014;130:364-373.
3. Fagiolini A, Forgione R, Maccari M, Cuomo A, Morana B, Dell'Osso MC, et al. Prevalence, chronicity, burden and borders of bipolar disorder. J Affect Disord 2013;148:161-169.
4. Knežević V, Nedić A. Influence of misdiagnosis on the course of bipolar disorder. Eur Rev Med Pharmacol Sci 2013;17:1542-1545.
5. Leboyer M, Kupfer DJ. Bipolar disorder: new perspectives in health care and prevention. J Clin Psychiatry 2010;71: 1689-1695
6. Barbosa IG, Bauer ME, Machado-Vieira R, Teixeira AL. Cytokines in bipolar disorder: paving the way for neuroprogression. Neural Plast 2014;2014:360481.
7. Conus P, Macneil C, McGorry PD. Public health significance of bipolar disorder: implications for early intervention and prevention. Bipolar Disord 2014;16:548-556.
8. Frank E, Nimgaonkar VL, Phillips ML, Kupfer DJ. All the world's a (clinical) stage: rethinking bipolar disorder from a longitudinal perspective. Mol Psychiatry 2015;20:23-31
9. Kapczinski F, Magalhães PV, Balanzá-Martinez V, Dias VV, Frangou S, Gama CS, et al. Staging systems in bipolar disorder: an International Society for Bipolar Disorders Task Force Report. Acta Psychiatr Scand 2014;130:354-363
10. Duffy A, Carlson GA. How does a developmental perspective inform us about the early Natural History of Bipolar Disorder? J Can Acad Child Adolesc Psychiatry 2013;22:6-12
11. Zivanovic O, Nedic A. Kraepelin's concept of manic-depressive insanity: one hundred years later. J Affect Disord 2012;137: 15-24
12. McGorry P, Keshavan M, Goldstone S, Amminger P, Allott K, Berk M, et al. Biomarkers and clinical staging in psychiatry. World Psychiatry 2014;13:211-223
13. Berk M, Hallam K, Malhi GS, Henry L, Hasty M, Macneil C, et al. Evidence and implications for early intervention in bipolar disorder. J Ment Health 2010;19:113-126
14. Rybakowski JK. Response to lithium in bipolar disorder: clinical and genetic findings. ACS Chem Neurosci 2014;5: 413-421
15. Rybakowski JK. Factors associated with lithium efficacy in bipolar disorder. Harv Rev Psychiatry 2014;22:353-357
16. Duffy A. The early natural history of bipolar disorder: what we have learned from longitudinal high-risk research. Can J Psychiatry 2010;55:477-485
17. Grof P. Sixty years of lithium responders. Neuropsychobiology 2010;62:8-16
18. Grof P, Duffy A, Alda M, Hajek T. Lithium response across generations. Acta Psychiatr Scand 2009;120:378-385
19. Garnham J, Munro A, Slaney C, Macdougall M, Passmore M, Duffy A, et al. Prophylactic treatment response in bipolar disorder: results of a naturalistic observation study. J Affect Disord 2007;104:185-190
20. Duffy A, Alda M, Kutcher S, Cavazzoni P, Robertson C, Grof E, et al. A prospective study of the offspring of bipolar parents responsive and nonresponsive to lithium treatment. J Clin Psychiatry 2002;63:1171-1178
21. Alda M. The phenotypic spectra of bipolar disorder. Eur Neuropsychopharmacol 2004;14 Suppl 2:S94-S99
22. Duffy A, Horrocks J, Doucette S, Keown-Stoneman C, McCloskey S, Grof P. The developmental trajectory of bipolar disorder. Br J Psychiatry 2014;204:122-128
23. Duffy A, Alda M, Hajek T, Grof P. Early course of bipolar disorder in high-risk offspring: prospective study Br J Psychiatry 2009;195:457-458
24. Goldstein BI, Shamseddeen W, Axelson DA, Kalas C, Monk K, Brent DA, et al. Clinical, demographic, and familial correlates of bipolar spectrum disorders among offspring of parents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2010;49:388-396
25. Levy B, Manove E. Functional outcome in bipolar disorder: the big picture. Depress Res Treat 2012;2012:949248
26. Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011;35: 804-817
27. Mesman E, Nolen WA, Reichart CG, Wals M, Hillegers MH. The Dutch bipolar offspring study: 12-year follow-up Am J Psychiatry 2013;170:542-549
28. Sparks GM, Axelson DA, Yu H, Ha W, Ballester J, Diler RS, et al. Disruptive mood dysregulation disorder and chronic irritability in youth at familial risk for bipolar disorder. J Am Acad Child Adolesc Psychiatry 2014;53:408-416
29. Masi G, Mucci M, Pfanner C, Berloffa S, Magaz A, Perugi G. Developmental pathways for different subtypes of earlyonset bipolarity in youths. J Clin Psychiatry 2012;73:1335-1341
30. Singh MK, Ketter T, Chang KD. Distinguishing bipolar disorder from other psychiatric disorders in children. Curr Psychiatry Rep 2014;16:516
31. McNamara RK, Nandagopal JJ, Strakowski SM, DelBello MP. Preventative strategies for early-onset bipolar disorder: towards a clinical staging model CNS Drugs 2010;24:983-996
32. Duffy A, Alda M, Crawford L, Milin R, Grof P. The early manifestations of bipolar disorder: a longitudinal prospective study of the offspring of bipolar parents. Bipolar Disord 2007;9:828-838
33. Duffy A, Alda M, Milin R, Grof P. A consecutive series of treated affected offspring of parents with bipolar disorder: is response associated with the clinical profile? Can J Psychiatry 2007;52:369-376
34. Faedda GL, Marangoni C, Serra G, Salvatore P, Sani G, Vázquez GH, et al. Precursors of bipolar disorders: a systematic literature review of prospective studies. J Clin Psychiatry 2015;76:614-624
35. Duffy A. Toward a comprehensive clinical staging model for bipolar disorder: integrating the evidence. Can J Psychiatry 2014;59:659-666
36. Valentí M, Pacchiarotti I, Undurraga J, Bonnín CM, Popovic D, Goikolea JM, et al. Risk factors for rapid cycling in bipolar disorder. Bipolar Disord 2015;17:549-559
37. Tidemalm D, Haglund A, Karanti A, Landén M, Runeson B. Attempted suicide in bipolar disorder: risk factors in a cohort of 6086 patients. PLoS One 2014;9:e94097
38. Kim MD, Seo HJ, Yun HJ, Jung YE, Park JH, Lee CI, et al. The relationship between cognitive decline and psychopathology in patients with schizophrenia and bipolar disorder. Clin Psychopharmacol Neurosci 2015;13:103-108
39. Gama CS, Kunz M, Magalhães PV, Kapczinski F. Staging and neuroprogression in bipolar disorder: a systematic review of the literature. Rev Bras Psiquiatr 2013;35:70-74
40. Fries GR, Pfaffenseller B, Stertz L, Paz AV, Dargél AA, Kunz M, et al. Staging and neuroprogression in bipolar disorder. Curr Psychiatry Rep 2012;14:667-675
41. Bizik G, Picard M, Nijjar R, Tourjman V, McEwen BS, Lupien SJ, et al. Allostatic load as a tool for monitoring physiological dysregulations and comorbidities in patients with severe mental illnesses. Harv Rev Psychiatry 2013;21: 296-313
42. Grande I, Magalhães PV, Kunz M, Vieta E, Kapczinski F. Mediators of allostasis and systemic toxicity in bipolar disorder. Physiol Behav 2012;106:46-50
43. Kapczinski F, Vieta E, Andreazza AC, Frey BN, Gomes FA, Tramontina J, et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci Biobehav Rev 2008;32:675-692
44. McEwen BS. Protective and damaging effects of stress mediators: central role of the brain. Dialogues Clin Neurosci 2006;8:367-381
45. Strakowski SM, DelBello MP, Zimmerman ME, Getz GE, Mills NP, Ret J, et al. Ventricular and periventricular structural volumes in first- versus multiple-episode bipolar disorder. Am J Psychiatry 2002;159:1841-1847
46. Moorhead TW, McKirdy J, Sussmann JE, Hall J, Lawrie SM, Johnstone EC, et al. Progressive gray matter loss in patients with bipolar disorder. Biol Psychiatry 2007;62:894-900
47. Lápez-Larson MP, DelBello MP, Zimmerman ME, Schwiers ML, Strakowski SM. Regional prefrontal gray and white matter abnormalities in bipolar disorder. Biol Psychiatry 2002;52:93-100
48. Kempton MJ, Geddes JR, Ettinger U, Williams SC, Grasby PM. Meta-analysis, database, and meta-regression of 98 structural imaging studies in bipolar disorder Arch Gen Psychiatry 2008;65:1017-1032
49. Gulseren S, Gurcan M, Gulseren L, Gelal F, Erol A. T2 hyperintensities in bipolar patients and their healthy siblings. Arch Med Res 2006;37:79-85
50. Fernandes BS, Gama CS, Ceresér KM, Yatham LN, Fries GR, Colpo G, et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis J Psychiatr Res 2011;45:995-1004
51. Lin PY. State-dependent decrease in levels of brain-derived neurotrophic factor in bipolar disorder: a meta-analytic study Neurosci Lett 2009;466:139-143
52. Serum brain-derived neurotrophic factor in bipolar and unipolar depression: a potential adjunctive tool for differential diagnosis. J Psychiatr Res 2009;43:1200-1204
53. Grande I, Fries GR, Kunz M, Kapczinski F. The role of BDNF as a mediator of neuroplasticity in bipolar disorder. Psychiatry Investig 2010;7:243-250
54. Kapczinski F, Fernandes BS, Kauer-Sant'Anna M, Gama CS, Yatham LN, Berk M The concept of staging in bipolar disorder: the role of BDNF and TNF-alpha as biomarkers. Acta Neuropsychiatr 2009;21:272-274
55. Tramontina JF Andreazza AC Kauer-Sant'anna M. Stertz L. Goi J. Chiarani F. et al. Brain-derived neurotrophic factor serum levels before and after treatment for acute mania Neurosci Lett 2009 452 111-113.
56. Pfaffenseller B, Fries GR, Wollenhaupt-Aguiar B, Colpo GD, Stertz L, Panizzutti B, et al Neurotrophins, inflammation and oxidative stress as illness activity biomarkers in bipolar disorder. Expert Rev Neurother 2013 13 827-842.
57. Chitty KM, Lagopoulos J, Hickie IB, Hermens DF A longitudinal proton magnetic resonance spectroscopy study investigating oxidative stress as a result of alcohol and tobacco use in youth with bipolar disorder. J Affect Disord 2015 175 481-487.
58. Teixeira AL, Barbosa IG, Machado-Vieira R, Rizzo LB, Wieck A, Bauer ME. Novel biomarkers for bipolar disorder. Expert Opin Med Diagn 2013;7:147-159
59. Andreazza AC, Kauer-Sant'anna M, Frey BN, Bond DJ, Kapczinski F, Young LT, et al Oxidative stress markers in bipolar disorder: a meta-analysis J Affect Disord 2008 111 135-144.
60. Andreazza AC, Cassini C, Rosa AR, Leite MC, de Almeida LM, Nardin P, et al Serum S100B and antioxidant enzymes in bipolar patients. J Psychiatr Res 2007 41 523-529.
61. Savas HA, Gergerlioglu HS, Armutcu F, Herken H, Yilmaz HR, Kocoglu E, et al Elevated serum nitric oxide and superoxide dismutase in euthymic bipolar patients: impact of past episodes. World J Biol Psychiatry 2006 7 51-55.
62. Andreazza AC, Kapczinski F, Kauer-Sant'Anna M, Walz JC, Bond DJ, Gonçalves CA, et al 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. J Psychiatry Neurosci 2009;34: 263-271
63. Andreazza AC, Frey BN, Erdtmann B, Salvador M, Rombaldi F, Santin A, et al DNA damage in bipolar disorder. Psychiatry Res 2007 153 27-32.
64. Elvsåshagen T, Vera E, Boen E, Bratlie J, Andreassen OA, Josefsen D, et al The load of short telomeres is increased and associated with lifetime number of depressive episodes in bipolar II disorder. J Affect Disord 2011 135 43-50.
65. Saretzki G, Von Zglinicki T Replicative aging, telomeres, and oxidative stress. Ann N Y Acad Sci 2002 959 24-29.
66. Simon NM, Smoller JW, McNamara KL, Maser RS, Zalta AK, Pollack MH, et al Telomere shortening and mood disorders: preliminary support for a chronic stress model of accelerated aging. Biol Psychiatry 2006 60 432-435.
67. Magalhães PV, Dean OM, Bush AI, Copolov DL, Malhi GS, Kohlmann K, et al N-acetylcysteine for major depressive episodes in bipolar disorder. Rev Bras Psiquiatr 2011 33 374-378.
68. Khairova R, Pawar R, Salvadore G, Juruena MF, de Sousa RT, Soeiro-de-Souza MG, et al Effects of lithium on oxidative stress parameters in healthy subjects. Mol Med Rep 2012 5 680-682.
69. Kapczinski F, Dal-Pizzol F, Teixeira AL, Magalhaes PV, Kauer-Sant'Anna M, Klamt F et al A systemic toxicity index developed to assess peripheral changes in mood episodes. Mol Psychiatry 2010 15 784-786.
70. Brietzke E, Kapczinski F TNF-alpha as a molecular target in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008 32 1355-1361.
71. Kim YK, Jung HG, Myint AM, Kim H, Park SH. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder J Affect Disord 2007;104:91-95
72. Leboyer M, Soreca I, Scott J, Frye M, Henry C, Tamouza R, et al Can bipolar disorder be viewed as a multi-system inflammatory disease? J Affect Disord 2012 141 1-10.
73. Hamdani N, Doukhan R, Kurtlucan O, Tamouza R, Leboyer M. Immunity, inflammation, and bipolar disorder: diagnostic and therapeutic implications. Curr Psychiatry Rep 2013;15: 387
74. Kauer-Sant'Anna M, Kapczinski F, Andreazza AC, Bond DJ, Lam RW, Young LT, et al Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. latestage bipolar disorder. Int J Neuropsychopharmacol 2009; 12:447-458
75. Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R. Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder Prog Neuropsychopharmacol Biol Psychiatry 2007;31:952-955
76. Drake C, Boutin H, Jones MS, Denes A, McColl BW, Selvarajah JR, et al Brain inflammation is induced by comorbidities and risk factors for stroke. Brain Behav Immun 2011 25 1113-1122.
77. Evans-Lacko SE, Zeber JE, Gonzalez JM, Olvera RL. Medical comorbidity among youth diagnosed with bipolar disorder in the United States. J Clin Psychiatry 2009;70: 1461-1466
78. Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry 2009 70 1078-1090.
79. Berk M, Hallam KT, McGorry PD. The potential utility of a staging model as a course specifier: a bipolar disorder perspective. J Affect Disord 2007;100:279-281
80. Kapczinski F, Dias VV, Kauer-Sant'Anna M, Frey BN, Grassi-Oliveira R, Colom F, et al Clinical implications of a staging model for bipolar disorders. Expert Rev Neurother 2009;9:957-966
81. Berk M, Berk L, Dodd S, Cotton S, Macneil C, Daglas R, et al Stage managing bipolar disorder. Bipolar Disord 2014 16 471-477.
82. Berk M, Malhi GS, Hallam K, Gama CS, Dodd S, Andreazza AC, et al Early intervention in bipolar disorders: clinical, biochemical and neuroimaging imperatives. J Affect Disord 2009 114 1-13.
83. McIntyre RS, Soczynska JK, Cha DS, Woldeyohannes HO, Dale RS, Alsuwaidan MT, et al. The prevalence and illness characteristics of DSM-5-defined "mixed feature specifier" in adults with major depressive disorder and bipolar disorder: Results from the International Mood Disorders Collaborative Project J Affect Disord 2014;172C:259-264
84. Benazzi F. The continuum/spectrum concept of mood disorders: is mixed depression the basic link? Eur Arch Psy chiatry Clin Neurosci 2006;256:512-515
85. Musselman D, Royster EB, Wang M, Long Q, Trimble LM, Mann TK, et al The impact of escitalopram on IL-2-induced neuroendocrine, immune, and behavioral changes in patients with malignant melanoma: preliminary findings Neuropsychopharmacology 2013 38 1921-1928.
86. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatmentresistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013 70 31-41.
87. Moylan S, Maes M, Wray NR, Berk M The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry 2013 18 595-606.
88. Ferensztajn E, Remlinger-Molenda A, Rybakowski J Staging of unipolar affective illness. Psychiatr Pol 2014 48 1127-1141.